Yoshito Takeuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshito Takeuchi has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Natsuko Hayashi
Department of Radiology, North Medical Center, Kyoto Prefectural University of Medicine, Yosanocho, Japan
5 shared publications - Yasuaki Arai
Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
5 shared publications - Kei Yamada
Kyoto Prefectural University of Medicine
4 shared publications - Hiroshi Miura
Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications - Hiroyuki Morishita
Department of Diagnostic Radiology, Japan Red Cross Kyoto Daiichi Hospital, Higashiyama, Japan
3 shared publications - Koji Sakai
Kyoto Prefectural University of Medicine
3 shared publications
Latest Publications
- 15 February 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (4) , 522-526
CT-Guided Femoral Approach for Psoas Muscle Abscess Drainage
Purpose To evaluate the feasibility and safety of the computed tomography (CT)-guided femoral approach for draining a psoas muscle abscess (PMA). Materials and Methods Between January 2014 and November 2018, the CT-guided femoral approach was employed for 9 abscesses in 8 patients who could not tolerate the prone position because of advanced age or other underlying conditions. A 17-gauge blunt metal needle was used to puncture the iliacus muscle below the groin under CT fluoroscopic guidance. A drainage catheter was then placed within the abscess cavity in the psoas major muscle. Technical success, clinical success, complications, the drainage therapy duration, susceptibility to antibiotics, survival, and recurrence were evaluated. Results The technical success rate was 100% among all nine lesions. The clinical success rate was 89% among all eight patients. One patient died of concomitant meningitis 15 days after the procedure. No patients developed therapy-related complications. The median duration of the drainage therapy was 15 days (range 6–71 days). Appropriate antibiotics based on the culture susceptibility were achieved in all patients. Four patients survived, and the remaining four died at 15 to 758 days (median, 36 days) after the procedure; no therapy-related deaths occurred. No recurrence was seen. Conclusion The CT-guided femoral approach seems feasible, effective, and safe for draining psoas muscle abscesses in ill patients who cannot tolerate the prone position.
- 15 February 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (4) , 522-526
CT-Guided Femoral Approach for Psoas Muscle Abscess Drainage
Purpose To evaluate the feasibility and safety of the computed tomography (CT)-guided femoral approach for draining a psoas muscle abscess (PMA). Materials and Methods Between January 2014 and November 2018, the CT-guided femoral approach was employed for 9 abscesses in 8 patients who could not tolerate the prone position because of advanced age or other underlying conditions. A 17-gauge blunt metal needle was used to puncture the iliacus muscle below the groin under CT fluoroscopic guidance. A drainage catheter was then placed within the abscess cavity in the psoas major muscle. Technical success, clinical success, complications, the drainage therapy duration, susceptibility to antibiotics, survival, and recurrence were evaluated. Results The technical success rate was 100% among all nine lesions. The clinical success rate was 89% among all eight patients. One patient died of concomitant meningitis 15 days after the procedure. No patients developed therapy-related complications. The median duration of the drainage therapy was 15 days (range 6–71 days). Appropriate antibiotics based on the culture susceptibility were achieved in all patients. Four patients survived, and the remaining four died at 15 to 758 days (median, 36 days) after the procedure; no therapy-related deaths occurred. No recurrence was seen. Conclusion The CT-guided femoral approach seems feasible, effective, and safe for draining psoas muscle abscesses in ill patients who cannot tolerate the prone position.
- Open Access
- 6 December 2021
- Published by Wiley in Cancer Science
- Vol. 113 (3) , 1010-1017
A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
Xentuzumab is an insulin‐like growth factor (IGF) ligand‐neutralizing antibody. This phase 1 trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged ≥20 y old with solid tumors that were refractory or not amenable to standard therapy were enrolled. Patients received xentuzumab intravenously at a starting dose of 750 mg/wk. Dose escalation used a 3 + 3 design with dose de‐escalation. The primary endpoint was to determine the maximum tolerated dose (MTD) of xentuzumab. Safety, pharmacokinetics, pharmacodynamics, and anti‐tumor activity were also assessed. Fifteen patients received xentuzumab in the dose escalation part (750 mg/wk [n = 6]; 1000 mg/wk [n = 3]; 1400 mg/wk [n = 6]). There were no dose‐limiting toxicities at any dose; the MTD of xentuzumab was not reached. Xentuzumab 1000 mg/wk was recommended as the relevant biological dose. Six further patients received xentuzumab 1000 mg/wk in an expansion cohort. Of 21 patients, 13 (61.9%) experienced a drug‐related adverse event, most commonly fatigue (23.8%), neutropenia (19.0%), diarrhea, nausea, white blood cell count decrease, and muscle spasms (14.3% each). No relevant deviations from dose linearity of xentuzumab exposure were observed during dose escalation. Total IGF‐1 and IGF‐2 levels increased and bioactive IGF levels decreased from baseline to 24 h after the first infusion in cycle 1. Partial response was observed in 2 (9.5%) patients with desmoid‐type fibromatosis. Disease control was achieved in 6 (28.6%) patients (median duration 42.4 mo). Xentuzumab monotherapy was well tolerated in Japanese patients and showed evidence of anti‐tumor activity. This study was registered with www.clinicaltrials.gov (NCT02145741).
- 6 December 2021
- Published by Wiley in Cancer Science
- Vol. 113 (3) , 1010-1017
Open AccessA phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
Xentuzumab is an insulin‐like growth factor (IGF) ligand‐neutralizing antibody. This phase 1 trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged ≥20 y old with solid tumors that were refractory or not amenable to standard therapy were enrolled. Patients received xentuzumab intravenously at a starting dose of 750 mg/wk. Dose escalation used a 3 + 3 design with dose de‐escalation. The primary endpoint was to determine the maximum tolerated dose (MTD) of xentuzumab. Safety, pharmacokinetics, pharmacodynamics, and anti‐tumor activity were also assessed. Fifteen patients received xentuzumab in the dose escalation part (750 mg/wk [n = 6]; 1000 mg/wk [n = 3]; 1400 mg/wk [n = 6]). There were no dose‐limiting toxicities at any dose; the MTD of xentuzumab was not reached. Xentuzumab 1000 mg/wk was recommended as the relevant biological dose. Six further patients received xentuzumab 1000 mg/wk in an expansion cohort. Of 21 patients, 13 (61.9%) experienced a drug‐related adverse event, most commonly fatigue (23.8%), neutropenia (19.0%), diarrhea, nausea, white blood cell count decrease, and muscle spasms (14.3% each). No relevant deviations from dose linearity of xentuzumab exposure were observed during dose escalation. Total IGF‐1 and IGF‐2 levels increased and bioactive IGF levels decreased from baseline to 24 h after the first infusion in cycle 1. Partial response was observed in 2 (9.5%) patients with desmoid‐type fibromatosis. Disease control was achieved in 6 (28.6%) patients (median duration 42.4 mo). Xentuzumab monotherapy was well tolerated in Japanese patients and showed evidence of anti‐tumor activity. This study was registered with www.clinicaltrials.gov (NCT02145741).
- 2 October 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (12) , 1953
Correction to: Reply to the letter: N-Butyl Cyanoacrylate–Lipiodol Mixture for Endovascular Purpose: Polymerization Kinetics Differences Between In Vitro and In Vivo Experiments
We would like to correct one of the references that was listed incorrectly in our article.
- 2 October 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (12) , 1953
Correction to: Reply to the letter: N-Butyl Cyanoacrylate–Lipiodol Mixture for Endovascular Purpose: Polymerization Kinetics Differences Between In Vitro and In Vivo Experiments
We would like to correct one of the references that was listed incorrectly in our article.
- 28 January 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (5) , 803-805
Combination Use of a Curved Tip Introducer Needle and a Straight Coaxial Needle to Facilitate an Intrahepatic Puncture During Percutaneous Transhepatic Intrahepatic Portosystemic Shunt (PTIPS)
- 28 January 2020
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (5) , 803-805
Combination Use of a Curved Tip Introducer Needle and a Straight Coaxial Needle to Facilitate an Intrahepatic Puncture During Percutaneous Transhepatic Intrahepatic Portosystemic Shunt (PTIPS)
- 12 December 2019
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (4) , 630-635
Is the Cessation of Blood Flow Faster than the Polymerization of an n-Butyl Cyanoacrylate–Lipiodol Mixture? An In Vitro Phantom Study
To compare the polymerization time of n-butyl cyanoacrylate (NBCA) and lipiodol mixture in a static model and a pulsating flow model simulating embolization procedure of small caliber arteries.
- 12 December 2019
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 43 (4) , 630-635
Is the Cessation of Blood Flow Faster than the Polymerization of an n-Butyl Cyanoacrylate–Lipiodol Mixture? An In Vitro Phantom Study
To compare the polymerization time of n-butyl cyanoacrylate (NBCA) and lipiodol mixture in a static model and a pulsating flow model simulating embolization procedure of small caliber arteries.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi119
Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors
Background: BI 836845 is an insulin-like growth factor (IGF) ligand-neutralizing humanized antibody that binds to IGF-1/IGF-2 ligands. This Phase I trial (NCT02145741) evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and activity of BI 836845.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi119
Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors
Background: BI 836845 is an insulin-like growth factor (IGF) ligand-neutralizing humanized antibody that binds to IGF-1/IGF-2 ligands. This Phase I trial (NCT02145741) evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and activity of BI 836845.
- 28 December 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (6) , 920-926
Balloon Blocking Technique (BBT) for Superselective Catheterization of Inaccessible Arteries with Conventional and Modified Techniques
Purpose The purpose of the study was to retrospectively evaluate the efficacy and safety of the balloon blocking technique (BBT). Materials and Methods The BBT was performed in six patients (all males, mean 73.5 years) in whom superselective catheterization for transcatheter arterial embolization by the conventional microcatheter techniques had failed due to anatomical difficulty, including targeted arteries originating steeply or hooked from parent arteries. All BBT procedures were performed using Seldinger’s transfemoral method. Occlusive balloons were deployed and inflated at the distal side of the target artery branching site in the parent artery via transfemoral access. A microcatheter was delivered from a 5-F catheter via another femoral access and was advanced over the microguidewire into the target artery, under balloon blockage of advancement of the microguidewire into non-target branches. After the balloon catheter was deflated and withdrawn, optimal interventions were performed through the microcatheter. Results After success of accessing the targeted artery by BBT, optimal interventions were accomplished in all patients with no complications other than vasovagal hypotension, which responded to nominal therapy. Conclusion The BBT may be useful in superselective catheterization of inaccessible arteries due to anatomical difficulties.
- 28 December 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (6) , 920-926
Balloon Blocking Technique (BBT) for Superselective Catheterization of Inaccessible Arteries with Conventional and Modified Techniques
Purpose The purpose of the study was to retrospectively evaluate the efficacy and safety of the balloon blocking technique (BBT). Materials and Methods The BBT was performed in six patients (all males, mean 73.5 years) in whom superselective catheterization for transcatheter arterial embolization by the conventional microcatheter techniques had failed due to anatomical difficulty, including targeted arteries originating steeply or hooked from parent arteries. All BBT procedures were performed using Seldinger’s transfemoral method. Occlusive balloons were deployed and inflated at the distal side of the target artery branching site in the parent artery via transfemoral access. A microcatheter was delivered from a 5-F catheter via another femoral access and was advanced over the microguidewire into the target artery, under balloon blockage of advancement of the microguidewire into non-target branches. After the balloon catheter was deflated and withdrawn, optimal interventions were performed through the microcatheter. Results After success of accessing the targeted artery by BBT, optimal interventions were accomplished in all patients with no complications other than vasovagal hypotension, which responded to nominal therapy. Conclusion The BBT may be useful in superselective catheterization of inaccessible arteries due to anatomical difficulties.
- 22 December 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (5) , 717-723
Phase I/II Study of Radiofrequency Ablation for Malignant Renal Tumors: Japan Interventional Radiology in Oncology Study Group 0701
This multicenter phase I/II study evaluated the safety, feasibility, and initial efficacy of radiofrequency ablation (RFA) for small malignant renal tumors. Thirty-three patients were enrolled in the study. A single session of RFA was performed in patients with a renal tumor of 1–3 cm in greatest diameter, with the exception of lesions adjacent to the renal hilum. The primary endpoint was the safety of renal RFA, and the secondary endpoints were its feasibility and initial efficacy for local control, as well as the incidence and grade of adverse events. Clinical efficacy was evaluated by CT scans within 1 week and at a further 4 weeks after the procedure using the criteria adapted from the Response Evaluation Criteria in Solid Tumors. The RFA procedure was completed in 100 % (95 % confidence interval [CI] 89–100 %) of all 33 patients. There were no severe adverse events (0 % [95 % CI 0–11 %]). Among the 33 patients, a complete response, partial response, progressive disease, and stable disease were seen in 28 (85 %), 0 (0 %), one (3 %), and one (3 %) patient(s), respectively, with a tumor response rate of 85 % [95 % CI 68–95 %]). Three patients (9 %), including one ineligible patient (3 %), were not evaluable. Out of 30 evaluable patients, a complete response was achieved in 28 (93 %). The current multicenter trial revealed that RFA is a safe, feasible, and effective treatment for small malignant renal tumors in patients who are not candidates for surgery.
- 22 December 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (5) , 717-723
Phase I/II Study of Radiofrequency Ablation for Malignant Renal Tumors: Japan Interventional Radiology in Oncology Study Group 0701
This multicenter phase I/II study evaluated the safety, feasibility, and initial efficacy of radiofrequency ablation (RFA) for small malignant renal tumors. Thirty-three patients were enrolled in the study. A single session of RFA was performed in patients with a renal tumor of 1–3 cm in greatest diameter, with the exception of lesions adjacent to the renal hilum. The primary endpoint was the safety of renal RFA, and the secondary endpoints were its feasibility and initial efficacy for local control, as well as the incidence and grade of adverse events. Clinical efficacy was evaluated by CT scans within 1 week and at a further 4 weeks after the procedure using the criteria adapted from the Response Evaluation Criteria in Solid Tumors. The RFA procedure was completed in 100 % (95 % confidence interval [CI] 89–100 %) of all 33 patients. There were no severe adverse events (0 % [95 % CI 0–11 %]). Among the 33 patients, a complete response, partial response, progressive disease, and stable disease were seen in 28 (85 %), 0 (0 %), one (3 %), and one (3 %) patient(s), respectively, with a tumor response rate of 85 % [95 % CI 68–95 %]). Three patients (9 %), including one ineligible patient (3 %), were not evaluable. Out of 30 evaluable patients, a complete response was achieved in 28 (93 %). The current multicenter trial revealed that RFA is a safe, feasible, and effective treatment for small malignant renal tumors in patients who are not candidates for surgery.